Aclaris Therapeutics, Inc. (ACRS) stock
Close on Nov 12, 2026Market cap $588.80MP/E –Yield –
Aclaris Therapeutics, Inc. saw revenue fall 59.3% to $6.40M over the twelve months to Sep 30, 2026. Free cash flow was -$75.32M. At the latest close the market valued the company at $588.80M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $588.80M
- P/E ratio
- –
- Price to sales
- 91.98
- Price to book
- 3.53
- Dividend yield
- –
- Free cash flow yield
- -12.79%
Fundamentals
- Revenue
- $6.40M
- Net income
- -$79.63M
- EPS, diluted
- -$0.58
- Free cash flow
- -$75.32M
- Book value per share
- $1.12
- Diluted shares
- 149M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $4.34
- Open
- $4.29
- Day's range
- $4.00 – $4.33
- Volume
- 1,956,664
- Average volume (20 days)
- 2,550,375
- Index membership
- Russell 2000 (since Jun 2025), Russell 3000 (since Nov 2025)
- Beta (5 years)
- 1.14
- 52-week range
- $2.25 – $6.60
- RSI (14 days)
- 48.7
- Volatility (1 year)
- 98.3%
- Relative volume
- 0.75×
- WACC
- 10.6%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | ACRS | S&P 500 | Difference | ACRS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.1% | -2.7% | +13.8 pts | ||
| 3 months | -31.5% | -1.7% | −29.8 pts | ||
| Year to date | +32.9% | +11.9% | +21.0 pts | ||
| 1 year | +66.0% | +12.0% | +54.0 pts | ||
| 3 years | -15.9% | +78.2% | −94.1 pts | -5.6% | +21.2% |
| 5 years | -73.2% | +73.2% | −146.4 pts | -23.1% | +11.6% |
| 10 years | -82.4% | +309.6% | −392.0 pts | -15.9% | +15.1% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Aclaris Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Aclaris Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biopharmaceutical business that discovers and develops drug candidates for immuno-inflammatory conditions. Its pipeline includes biological therapies such as bosakitug, a monoclonal antibody, and ATI-052, a bispecific antibody targeting inflammatory pathways. It also designs small molecule kinase inhibitors, including ATI-2138 and ATI-9494, using its proprietary drug discovery platform. The company develops these experimental therapies for individuals with autoimmune, dermatological, and respiratory disorders, including atopic dermatitis and asthma, and seeks partnerships with external pharmaceutical firms to advance and commercialize its treatments.
Company profile, executives and historyAclaris Therapeutics stock: common questions
What is Aclaris Therapeutics's stock price?
ACRS closed at $4.00 on Nov 12, 2026, down 7.83% on the day. Over the past 52 weeks it traded between $2.25 and $6.60.
What is Aclaris Therapeutics's market cap?
Aclaris Therapeutics was worth $588.80M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is ACRS's P/E ratio?
Aclaris Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.58), so it has no meaningful P/E ratio.
How much revenue does Aclaris Therapeutics make?
Aclaris Therapeutics reported revenue of $6.40M for the twelve months to Sep 30, 2026, down 59.3% from a year earlier.
Does Aclaris Therapeutics pay a dividend?
No. Aclaris Therapeutics has not paid a cash dividend over the last twelve months.
When does Aclaris Therapeutics report earnings next?
Aclaris Therapeutics is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ACRS stock performed over the past year?
Including dividends, ACRS returned +66.0% over the past year, against +12.0% for the S&P 500.
How many ACRS shares are sold short?
12M shares were sold short at the latest FINRA report, 9.06% of the float, or 4.0 days of average trading volume.
Who are Aclaris Therapeutics's competitors?
Companies most similar to Aclaris Therapeutics by business, industry and size include ALMS, CNTB, ZBIO, HCWB, CAMP.
See a number that looks wrong?